vatalanib has been researched along with Fibrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brun, P; Castagliuolo, I; Chilin, A; Dalla Via, M; Marzaro, G; Palu', G; Schirato, G | 1 |
| Hirt, SW; Keil, L; Lehle, K; Schaub, AL; Schmid, C; von Suesskind-Schwendi, M | 1 |
2 other study(ies) available for vatalanib and Fibrosis
| Article | Year |
|---|---|
Substituted quinazolinones as kinase inhibitors endowed with anti-fibrotic properties.
Topics: Enzyme Inhibitors; Fibrosis; Molecular Docking Simulation; Quinazolinones | 2016 |
Synergism of imatinib, vatalanib and everolimus in the prevention of chronic lung allograft rejection after lung transplantation (LTx) in rats.
Topics: Animals; Bronchiolitis Obliterans; Drug Synergism; Everolimus; Fibrosis; Graft Rejection; Imatinib Mesylate; Immunohistochemistry; Lung Transplantation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred F344; Rats, Inbred WKY; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; TOR Serine-Threonine Kinases; Transplantation, Homologous; Vascular Endothelial Growth Factor Receptor-2 | 2019 |